The precision of TI hypointense lesion volume quantification in multiple sclerosis treatment trials: A multicenter study

P. D. Molyneux, P. A. Brex, C. Fogg, S. Lewis, C. Middleditch, F. Barkhof, M. P. Sormani, M. Filippi, D. H. Miller

Research output: Contribution to journalArticlepeer-review

Abstract

The volume of hypointense lesions on TI weighted brain MRI represents an increasingly used MR endpoint in phase III MS treatment trials. In this study we evaluated the reproducibility of hypointense TI lesion volume quantification in a cohort of Multiple Sclerosis (MS) patients. The gadolinium enhanced TI weighted brain MR images of 33 MS patients from three European centers were used in this study. These images were acquired as part of a phase III trial of interferon beta-I b in secondary progressive MS. The MRI machine manufacturers and imaging parameters varied according to the MRI acquisition center. Three experienced observers used a semi-automated local thresholding technique to quantify the hypointense TI lesion volume on two occasions, separated by a delay. The intra and inter observer coefficients of variation were 3.7% and 4.9% respectively, with similar values derived for images obtained at all three sites. There was a generally high level of agreement between the lesion volumes obtained by the three raters. However, a modest but significant measurement drift was identified between the first and second sessions for one of the three raters, highlighting the very real possibility of measurement drift even for experienced observers. Our results support the increasing role for TI hypointense lesion volume as an outcome measure in multicenter phase III MS treatment trials.

Original languageEnglish
Pages (from-to)237-240
Number of pages4
JournalMultiple Sclerosis Journal
Volume6
Issue number4
Publication statusPublished - 2000

Keywords

  • Magnetic resonance imaging
  • Multiple sclerosis
  • TI black hole

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'The precision of TI hypointense lesion volume quantification in multiple sclerosis treatment trials: A multicenter study'. Together they form a unique fingerprint.

Cite this